A family of products for critical size bone defects and skin wounds with unmet medical needs.

From advanced biopharmaceutical company Novadip Biosciences: a family of new generation, 3D therapies based on adipose stem cells, for hard and soft tissue reconstruction.

 

Market application for NVD-001: critical size bone defects with unmet medical needs.

Critical size bone defects following trauma, infection, congenital deficiency or tumour resection remain a major healthcare issue because of intrinsic difficulties in reconstructing large bone segments using bone implants with poor osteoinductive and disappointing osteogenic properties.

NVD-001 is a revolutionary approach to reconstruct large bone defects for long term improvement of quality of life in orthopaedics, neuro and maxillo-facial surgeries.

NVD-001 has the potential for distinct different indications:  neurosurgery for spine, orthopaedic surgery for trauma or tumour resection, cranial and maxillofacial surgery, osteonecrosis, consequences of osteoporosis pseudarthrosis, vertebral fractures etc.

The first clinical cases (15 patients) showed safety and efficacy, even in salvage situations where other technologies available were unsuccessful (>36 months FU for some patients).

bone-diseases-creost

 

Market application for NVD-002: skin wounds with unmet medical needs.

Various diseases, infections or traumas often result in skin wounds that do not heal spontaneously. Patients with diabetes, vascular ulcers or deep burns are particularly susceptible, and may require reconstructive surgery with skin autografts. However, this treatment is often disappointing because of the limited blood supply from the underlying wound structures prevent successful skin engraftment and cause large painful scars. These aesthetic and functional sequels cause body image distress and pain.

NVD-002 is designed to avoid formation of these scars. It could be applied in different indications including burn hypertrophic scars, chronic wounds in case of radionecrosis and systemic disease such as diabetes.

 

Potential market segments for critical size bone defects

(EU/US p.a.)

3.000.000

Spinal procedures

350.000

Bone tumor resections

200.000

Patients with osteonecrosis

500.000

Patients with non-unions or delayed unions

400.000

Patients with vertebral fractures

1.200.000

Patients with severe osteoporosis

3.000.000

Maxillofacial and periodontal treatments